 The similar mechanism of action of interferon and nitazoxanide suggest that stand-alone nitazoxanide therapy or nitazoxanide in concert with nucleos(t)ide analogs have the potential to increase loss of HBsAg, which is the ultimate end-point of therapy.A formal phase Ⅱ study is being planned for 2009.Romark initially decided to focus on the possibility of treating chronic hepatitis C with nitazoxanide.